Holen Sie sich die Stockscreener-App
8.00
5.77%
-0.49
Handel nachbörslich:
8.00
Schlusskurs vom Vortag:
$8.49
Offen:
$8.6
24-Stunden-Volumen:
470.16K
Relative Volume:
0.96
Marktkapitalisierung:
$492.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-153.16M
KGV:
-2.168
EPS:
-3.69
Netto-Cashflow:
$-134.48M
1W Leistung:
-8.26%
1M Leistung:
-20.48%
6M Leistung:
-56.78%
1J Leistung:
-56.78%
1-Tages-Spanne:
$7.95
$8.635
1-Wochen-Bereich:
$7.95
$8.87
52-Wochen-Spanne:
$7.95
$30.19
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Firmenname
Cullinan Therapeutics Inc
Sektor
Branche
Telefon
617-410-4650
Adresse
ONE MAIN STREET, CAMBRIDGE
Vergleichen Sie CGEM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
8.00 | 492.68M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-05-01 | Eingeleitet | Stifel | Buy |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-06-15 | Eingeleitet | TD Cowen | Outperform |
| 2022-11-21 | Eingeleitet | BTIG Research | Buy |
| 2021-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Eingeleitet | Evercore ISI | Outperform |
| 2021-02-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Eingeleitet | SVB Leerink | Outperform |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Q1 Earnings Estimate for CGEM Issued By William Blair - Defense World
Cullinan Therapeutics’ (CGEM) “Buy” Rating Reiterated at HC Wainwright - Defense World
Cullinan Therapeutics Inc (CGEM) Reports Q4 2024 Net Loss of $47 - GuruFocus.com
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Cullinan Therapeutics: Q4 Earnings Snapshot - The Pioneer
Cullinan Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Cullinan Therapeutics’ chief medical officer sells $41,754 in stock By Investing.com - Investing.com Canada
Cullinan Therapeutics CEO sells $106,872 in stock By Investing.com - Investing.com Canada
Cullinan Therapeutics’ chief medical officer sells $41,754 in stock - Investing.com India
Cullinan Therapeutics CEO sells $106,872 in stock - Investing.com India
Cullinan Therapeutics Reports Phase 1 Study Updates and Financial Results for Q4 2024 - Nasdaq
Cullinan Therapeutics, Inc. SEC 10-K Report - TradingView
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire Inc.
Financial Review: Cullinan Therapeutics (NASDAQ:CGEM) and Adaptimmune Therapeutics (NASDAQ:ADAP) - Defense World
Cullinan Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Exclusive Access: Cullinan Therapeutics Leadership Reveals Strategy at Elite Healthcare Forums - StockTitan
Prepare Yourself for Liftoff: Cullinan Therapeutics Inc (CGEM) - SETE News
CULLINAN ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com
Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 12-Month LowHere's Why - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Buy" by Analysts - MarketBeat
FY2024 Earnings Estimate for CGEM Issued By Leerink Partnrs - MarketBeat
What is Leerink Partnrs’ Forecast for CGEM FY2024 Earnings? - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Rating of “Buy” by Brokerages - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Sees Strong Trading VolumeWhat's Next? - MarketBeat
What is Leerink Partnrs’ Estimate for CGEM Q1 Earnings? - Defense World
Ratio Revelations: Cullinan Therapeutics Inc (CGEM)’s Financial Metrics in the Spotlight - The Dwinnex
CGEM Stock Sees Decline of Approximately -5.74% in Last Five Days - Knox Daily
Cullinan CEO talks autoimmune pivot, upcoming lupus readout and his 'thriller or killer' approach - Fierce Biotech
SG Americas Securities LLC Has $283,000 Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
HC Wainwright Has Bearish Outlook for CGEM FY2025 Earnings - MarketBeat
Equities Analysts Issue Forecasts for CGEM Q1 Earnings - MarketBeat
HC Wainwright Brokers Decrease Earnings Estimates for CGEM - Defense World
HC Wainwright Boosts Cullinan Therapeutics (NASDAQ:CGEM) Price Target to $33.00 - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up Following Analyst Upgrade - MarketBeat
Q1 Earnings Forecast for CGEM Issued By HC Wainwright - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Cullinan reports zipalertinib study met primary endpoint - MSN
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Cullinan Therapeutics Reveals Next-Gen Pipeline Details at Major Biotech Conference - StockTitan
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up After Analyst Upgrade - Defense World
Cullinan/Taiho’s Zipalertinib Stands To Benefit From A Clear Market - Citeline
Cullinan Management Achieves Milestone in Cancer Trial - TipRanks
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Bought by JPMorgan Chase & Co. - Defense World
Cullinan Therapeutics Says Zipalertinib Trial Met Primary Endpoint -January 29, 2025 at 04:38 am EST - Marketscreener.com
Cullinan Reveals Update On REZILIENT1 Trial Data For Zipalertinib In Non-Small Cell Lung Cancer - RTTNews
Game-Changing Lung Cancer Drug Shows Promise: New Hope for EGFR Mutation Patients - StockTitan
Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.45%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):